Ropes & Gray: Fulcrum Therapeutics, Sanofi to Collaborate on Muscular Dystrophy Therapy
May 14, 2024
May 14, 2024
BOSTON, Massachusetts, May 14 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray advised Fulcrum Therapeutics in a collaboration and license agreement with French pharmaceutical company Sanofi for the development and commercialization of losmapimod, an oral therapy being investigated for the treatment of the rare disease facioscapulohumeral muscular dystrophy (FSHD). Under the transaction announced on May 13, Sanofi obtains exclusive commercialization rights . . .
Ropes & Gray advised Fulcrum Therapeutics in a collaboration and license agreement with French pharmaceutical company Sanofi for the development and commercialization of losmapimod, an oral therapy being investigated for the treatment of the rare disease facioscapulohumeral muscular dystrophy (FSHD). Under the transaction announced on May 13, Sanofi obtains exclusive commercialization rights . . .